MX2013014475A - COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR. - Google Patents

COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.

Info

Publication number
MX2013014475A
MX2013014475A MX2013014475A MX2013014475A MX2013014475A MX 2013014475 A MX2013014475 A MX 2013014475A MX 2013014475 A MX2013014475 A MX 2013014475A MX 2013014475 A MX2013014475 A MX 2013014475A MX 2013014475 A MX2013014475 A MX 2013014475A
Authority
MX
Mexico
Prior art keywords
antibodies
binding compounds
dsm
auto
adrenoreceptor
Prior art date
Application number
MX2013014475A
Other languages
English (en)
Inventor
Hans-Peter Holthoff
Martin Ungerer
Stefan Zeibig
Martin J Lohse
Roland Jahns
Valerie Jahns
Original Assignee
Corimmun Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corimmun Gmbh filed Critical Corimmun Gmbh
Publication of MX2013014475A publication Critical patent/MX2013014475A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos/compuestos de enlace que ligan al segundo bucle extracelular del ß1-adrenoreceptor humano (ß1-AR-ECII) que se producen por/obtienen de una célula huésped/hibridoma con un número de depósito seleccionado del grupo que consiste de DSM ACC3121, DSM ACC3174, DSM ACC3175, DSM ACC3176 y DSM ACC3177. Los anticuerpos/compuestos de enlace son particularmente útiles para determinar anticuerpos auto-anti-ß1-AR en un sistema de ensayo basado en células in vitro a fin de caracterizar e identificar autoanticuerpos dirigidos contra ß1-AR-ECII en una muestra biológica. Adicionales aspectos de la invención son moléculas de ácido nucleico que codifican los compuestos de enlace/anticuerpos, vectores, células huésped, métodos para producir los compuestos de enlace/anticuerpos de la invención así como un equipo que comprende los compuestos de enlace/anticuerpos de la presente invención.
MX2013014475A 2011-06-10 2012-06-06 COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR. MX2013014475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11169621 2011-06-10
PCT/EP2012/060776 WO2012168344A1 (en) 2011-06-10 2012-06-06 BINDING COMPOUNDS TO HUMAN β1-ADRENORECEPTOR (β1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-βA1-AR ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2013014475A true MX2013014475A (es) 2014-05-27

Family

ID=46465188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014475A MX2013014475A (es) 2011-06-10 2012-06-06 COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.

Country Status (10)

Country Link
US (1) US20140273015A1 (es)
EP (1) EP2718324A1 (es)
JP (1) JP2014519329A (es)
CN (1) CN104024275A (es)
AU (1) AU2012266363A1 (es)
BR (1) BR112013031590A2 (es)
CA (1) CA2835231A1 (es)
IL (1) IL229748A0 (es)
MX (1) MX2013014475A (es)
WO (1) WO2012168344A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160222084A1 (en) 2013-03-15 2016-08-04 The Board Of Regents Of The University Of Oklahoma Compositions Comprising D-Amino Acid Peptides and Methods of Production and Use Thereof for Inhibiting Autoantibodies
EP3652204A4 (en) * 2017-07-13 2021-04-21 Magarray, Inc. QUANTIFICATION PROCEDURES FOR AUTOANTIBODIES
WO2022169880A1 (en) * 2021-02-02 2022-08-11 The Cleveland Clinic Foundation Treatment of cvd and systemic sclerosis with beta-1 adrenergic receptor antibodies
KR20240099143A (ko) * 2021-08-27 2024-06-28 예일 유니버시티 세포외 단백질의 분자 분해제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
KR20020047177A (ko) 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
CN1468250A (zh) 2000-08-03 2004-01-14 ��ķһ����˹��̹ 在转基因动物中产生人源化抗体
WO2006103101A2 (en) 2005-03-31 2006-10-05 Julius-Maximilians-Universität Würzburg MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
CN1967249A (zh) * 2005-11-15 2007-05-23 华中科技大学同济医学院附属协和医院 抗心肌抗体四联诊断试剂盒
AU2008291296B2 (en) 2007-08-24 2014-02-06 Julius-Maximilians-Universitat Wurzburg Mutant double cyclized receptor peptides inhibiting beta1-adrenoceptor antibodies
DE102010018878B4 (de) 2009-04-30 2013-09-26 Julius-Maximilians-Universität Würzburg Neue Zell-Linie zur Fluoreszenz-basierten Detektion von funktionell aktiven Antikörpern und Autoantikörpern gegen den Beta1-adrenergen Rezeptor

Also Published As

Publication number Publication date
WO2012168344A1 (en) 2012-12-13
JP2014519329A (ja) 2014-08-14
CA2835231A1 (en) 2012-12-13
EP2718324A1 (en) 2014-04-16
WO2012168344A8 (en) 2013-03-14
CN104024275A (zh) 2014-09-03
BR112013031590A2 (pt) 2016-11-22
US20140273015A1 (en) 2014-09-18
IL229748A0 (en) 2014-01-30
AU2012266363A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
PH12014501091A1 (en) Binding molecules for bcma and cd3
EA201400709A1 (ru) Молекула биспецифического антитела
PH12015501651B1 (en) Antibody constructs for cdh19 and cd3
MX2015012862A (es) Moleculas de union para bcma y cd3.
MX2014002099A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
GB2549632A8 (en) Fusion protein comprising three binding domains to 5T4 and CD3
NZ799532A (en) Methods and means for the production of ig-like molecules
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX353144B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2012024650A3 (en) Anti-ngf antibodies and their use
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
MY181513A (en) Cell culture compositions and methods for polypeptide production
EP3009454A3 (en) Antibodies specific to cadherin-17
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
UA111340C2 (uk) Антитіло, яке специфічно зв'язується з tnf-альфа людини
CL2012002700A1 (es) Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4.
MX337203B (es) Novedosas moleculas inhbidoras de jnk.
MX2013014475A (es) COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
NZ605449A (en) Anti-neuropilin antibodies and methods of use
AR089028A1 (es) Composiciones y metodos para el analisis de cancer de prostata
MX2014011849A (es) Reactivos, procedimientos y kits para la clasificación del cáncer.
WO2012153186A3 (en) Monoclonal antibodies to epcam-icd and methods for detecting epithelial cancer cells